Appendix Cancer
Resources, Research, Referrals and Support for Appendiceal Cancer Patient
Pleural Metastasis in Appendix Cancer Patients
Clinicopathologic characteristics of patients with appendiceal adenocarcinoma (AA) and intra-thoracic metastasis.
Source: J Clin Oncol 30, 2012 (suppl 4; abstr 427)
Investigators: Joshua S. Hill, Safia Rafeeq, David C. Rice, Michael J. Overman, Richard E. Royal, Paul F. Mansfield, Keith F. Fournier; University of Texas M. D. Anderson Cancer Center, Houston, TX
Appendiceal adenocarcinoma (AA) is a rare disease with a prognosis related to tumor histology. Distant metastases, including those to the lung or pleura, are considered rare.
Study of 626 patients 1993-2009 at MDACC.
Conclusions: Intra-thoracic metastasis in patients with AA occurs at a higher rate than previously thought, even in low grade tumors. This suggests that thoracic imaging should be considered in patients with AA. Overall survival depends heavily on tumor histology.
This Week's Reports from ASCO
Appendix Cancer Staging
Improving the AJCC/TNM staging for Adenocarcinomas of the Appendix: The prognostic impact of histologic grade
Source: ASCO Abstract 402 GI Cancer Symposium 01.19.12
Source: ASCO Abstract 402 GI Cancer Symposium 01.19.12
Prognosis for Appendix Cancer Patients with Lymphatic Metastasis
Lymphatic metastasis in well differentiated appendiceal cancer: prognostic factors and associations with outcome.
Source: ASCO GI Cancer Abstract # 406 01.19.12
Source: ASCO GI Cancer Abstract # 406 01.19.12
WHO Proposed Uniform Classification for Appendix Cancer, Pseudomyxoma Peritonei
Mucinous Neoplasms of the Vermiform Appendix, Pseudomyxoma Peritonei, and the new WHO Classification.
Source
Pathologisches Institut, Ludwig-Maximilians-Universität München, Thalkirchner Str. 36, 80337, München, Deutschland simone.reu@med.uni-muenchen.de.
Abstract
Mucinous neoplasms of the appendix are rare tumors, some of them characterized by an enigmatic discrepancy between a benign morphologic appearance and an aggressive biologic potential, associated with a poor prognosis and high mortality.
The clinical picture of Pseudomyxoma Peritonei is, with few exceptions, caused by mucinous appendiceal neoplasms and differs in many aspects from usual Peritoneal Carcinomatosis.
The controversy regarding terminology, diagnostic criteria, classification and therapy of these tumors has lasted for decades.
The revised edition of the World Health Organization Classification of Tumors of the Digestive System proposes a uniform reporting system for mucinous appendiceal neoplasms and the peritoneal disease associated with it, thereby creating a comparable basis for pathological diagnosis, clinical therapy and further scientific studies.”
What is Appendix Cancer?
Appendix cancer, also described as appendiceal cancer, or an appendiceal epitheal neoplasm,occurs when cells multiply and grow abnormally, developing into tumors. .
Appendix Cancer tumors occur most often at, or near, the tip of the appendix. The cells multiply out of control and develop a growth of tissue, described as a tumor. Tumor can be either non cancerous, or benign, or cancerous, or malignant.
Appendiceal malignancies may be minimally invasive or aggressive. Malignant tumors may spread to other areas of the peritoneal cavity. However, dissemination of appendix cancer to the lymph nodes through the bloodstream is rare.
Symptoms may include pain in the lower right quadrant of the abdomen, acute appendicitis, abdominal bloating and distention, reflux, loss of appetite, digestive distress, infertility, and/or the appearance of a hernia.
Appendix cancer symptoms may appear to be subtle, and therefore, may initially be overlooked or misdiagnosed until they become especially problematic. It's important for patients, and especially for healthcare providers , to have awareness of these symptoms.
Due to an often common physical symptom of what is described as "expanding girth", male patients may intially be mis diagnosed with hernias while female patients may be misdiagnosed as having ovarian cancer.
See appendix cancer symptoms below for additional details.
Appendiceal mucocele is a rare diagnosis. It is estimated that approximately one thousand cases are diagnosed in the U.S. annually. On average, patients are diagnosed when they are in their mid forties.
Due to the rarity of this cancer and the rather vague symptoms, appendix cancer may be initially misdiagnosed. Male appendix cancer patients may be initially misdiagnosed as having a hernia, while female patients may be misdiagnosed as having ovarian cancer.
See Misdiagnosis below for additional details.
Appendix Cancer tumors are generally divided into two groups: carcinoid and non carcinoid. These carcinoid tumors occur most often at, or near, the tip of the appendix. Approximately half to two thirds of all appendix cancer tumors are carcinoid tumors. Carcinoid tumors originate in the hormone-producing cells that are usually present in small quantities in nearly every organ in the body.
Gastrointestinal carcinoid tumors form in cells that produce hormones along the lining of the gastrointestinal tract. These tumors usually appear in the small intestine, rectum and/or appendix. Gastrointestinal carcinoid tumors generally are considered to grow slowly, especially as when compared to other cancer tumors. Patients with gastrointestinal carcinoid tumors may have an increased risk of developing cancers in the digestive system.
Non carcinoid appendix tumors originate in the epithelial cells lining the appendix. These cells may create mucinous producing tumors. This gelatinous mucin production may put patients at risk for the eventual spread of tumor cells and the accompanying mucin, throughout the peritoneal cavity. Over time, this mucin, and the cancer cells can eventually cause bowel obstruction, if left untreated.
When accurately diagnosed and treated, the prognosis for appendix cancer patients can be quite good.
See appendix cancer prognosis for additional information.
Appendix cancer requires a specific treatment plan, provided by surgical oncologists who specialize in managing appendiceal cancer cases.
Adenocarcinoid tumors of the appendix, also known as goblet cell carcinomas (see below) are similar to both carcinoid and adenocarcinoma tumors.
Pathologist and expert, Dr Brigitte Ronnett, tells the PMP Pals' Network:
"We describe an adenocarcincoid as a relatively unusual tumor, typically arising in the appendix, and named for its histologic similarity to carcinoid tumors of the appendix (and other organs), combining features of carcinoid (usually goblet cell carcinoid) and adenocarcinoma, and thought to possibly have behavior between benign and adenocarcinoma, but, in our study, we found that appendiceal adenocarcinomas with adenocarcinoid appearance usually are infiltrative and aggressive, so we consider them a variant of adenocarcinoma (they have areas that resemble goblet cell carcinoid of the appendix, but also have signet ring cells, and other patterns of adenocarcinoma that are aggressive types of mucinous adenocarcinoma.)"
A neoplasm is defined as abnormal tissue that grows by cellular proliferation more rapidly than normal cells, and continues to grow after the stimuli that initiated the new growth cease. Neoplasms show partial or complete lack of structural organization and functional coordination with the normal tissue, and generally form a distinct mass of tissue that may be either benign (benign tumor) or malignant (cancer).
Find answers to your questions on this page!
What is appendix cancer?
What is appendiceal cancer?
What is an appendiceal adenocarcinoma?
What is an appendiceal epitheal neoplasm?
What is the cause of appendiceal cancer?
What is the treatment for appendix cancer?
Where can I find support through appendix cancer treatment?
What causes appendix cancer?
How can I connect with other appendix cancer survivors?
Where can I find a clinical trial for appendix cancer treatment?
What is the relationship between appendiceal cancer and colorectal cancer?
What is the relationship between appendix cancer and pseudomyxoma peritonei?
What Causes Cancer?
Appendix Cancer Symptom FAQs
What are the symptoms of appendiceal cancer?
How do I recognize Appendix Cancer symptoms?
How do I recognize Appendix Cancer symptoms?
Appendix Cancer Symptoms
Appendix cancer symptoms are often initially overlooked until they become problematic.
Symptoms may include pain in the lower right quadrant, bloating, abdominal distention, reflux, loss of appetite, digestive distress, appendicitis, appearance of a hernia, etc.
Symptoms of appendicitis may include inflammation, abdominal pain, swelling, vomiting, nausea, loss of appetite, constipation or diarrhea, and fever.
Due to an often common physical symptom of what is described as "expanding girth", male patients may intially be mis diagnosed with hernias while female patients may be misdiagnosed as having ovarian cancer.
The symptom or condition of ascites refers to the accumulation of fluid within the abdominal and/or peritoneal cavity. Ascites occur due a variety of benign and malignant conditions from inflammation to cancer.
Generally, the peritioneal cavity of a healthy adult includes approximately 100 ml. of pale colored, clear fluid. This fluid includes water, proteins, electrolytes and a variety of cell types. The cell types vary according to different pathological conditions. Lymphocytes in the fluid provide cellular, humoral, immunological defense mechanisms. The quantities and features of this fluid may change due to a variety of pathological conditions.
Symptoms may include pain in the lower right quadrant, bloating, abdominal distention, reflux, loss of appetite, digestive distress, appendicitis, appearance of a hernia, etc.
Symptoms of appendicitis may include inflammation, abdominal pain, swelling, vomiting, nausea, loss of appetite, constipation or diarrhea, and fever.
Due to an often common physical symptom of what is described as "expanding girth", male patients may intially be mis diagnosed with hernias while female patients may be misdiagnosed as having ovarian cancer.
The symptom or condition of ascites refers to the accumulation of fluid within the abdominal and/or peritoneal cavity. Ascites occur due a variety of benign and malignant conditions from inflammation to cancer.
Generally, the peritioneal cavity of a healthy adult includes approximately 100 ml. of pale colored, clear fluid. This fluid includes water, proteins, electrolytes and a variety of cell types. The cell types vary according to different pathological conditions. Lymphocytes in the fluid provide cellular, humoral, immunological defense mechanisms. The quantities and features of this fluid may change due to a variety of pathological conditions.
Appendix Cancer Diagnosis FAQs
How is Appendiceal Cancer diagnosed?
How does my doctor know I have Appendix Cancer?
Appendix Cancer Diagnosis
If you, or a loved one, have been diagnosed with Appendix Cancer, ask your physician for a specific diagnosis of your particular condition. Obtain a copy of, and review your pathology report.
Diagnosis may be suspected based on physical symptoms, CT scans and tumor marker tests. However, the actual diagnosis is confirmed by pathologists after examination of actual tissue and/or mucin or fluid samples.
Accurate diagnosis of Appendix Cancer, requires thorough sampling and investigation by both experienced surgeon(s) and experienced pathologist(s).
A variety of tests are utilize the confirm the diagnosis and assess the staging to determine appropriate treatment.
The most common tumor markers (see below) used for the monitoring and diagnosis of appendix cancer are the CEA and the CA 19-9.
The CT (Computerized Tomography) scanis the preferred method (preferred over PET or MRI) of scanning to detect and monitor appendix cancer.
Your physician may order additional or different tests based on your specific needs. Other tests may include a barium enema, colonoscopy, upper GI series or ultrasonography. However, generally these particular tests are not as effective, or may not be effective at all, in diagnosing or Appendix Cancer.
Ask your physician how the Peritoneal Cancer Index (see below) relates to your specific case.
A "final diagnosis" paragraph will clearly define your specific diagnosis, which may possibly include:
Pseudomyxoma Peritonei,
Mucinous Adenocarcinoma,
Mucinous Cystadenoma,
Disseminated Peritoneal Adenomucinosis or DPAM,
Signet Ring Cell Carcinoma of the Appendix,
Peritoneal Carcinomatosis,
Peritoneal Surface Malignancy or other diagnoses.
Appendiceal carcinoid tumors represent approximately fifty per cent of all appendix tumor cases.
Carcinoid tumors are usually less than two centimeters in size and rarely spred to lymph nodes.
Appendiceal non-carcinoid tumors originate from the epithelial cells lining the inside of the appendix.
These cells create tumors producing mucin (a gelatinous material defined as Pseudomyxoma Peritonei.)
These tumor cells and mucin (Pseudomyxoma Peritonei) can accumulate (increase) gradually taking more space within the abdominal or peritoneal cavity. If these mucin producing cells spread outside the appendix and into the peritoneal or abdominal cavity, they can lead to fatal bowel obstruction, if left untreated.
Appendiceal adenocarcinoid tumors and goblet cell carcinomas are similar to both carcinoid and adenocarcinoma tumors of the appendix.
Related Articles of Interest
Appendix Cancer Diagnosis: Rarely Diagnosed via Colonscopy
Source: Wake Forest University 2009
Appendix Cancer Diagnosis
Mucocele of the Appendix
Source: Pub Med 2007
Improved screening may be required for detection of Appendix Cancer diagnosis
Source: Cancer Journal of Gastroenterology, Canada 2009
Connect with other Appendix Cancer Patients!
Appendix Cancer Misdiagnosis
Appendiceal mucocele is a rare diagnosis. Due to the rarity of this cancer and the rather vague symptoms, appendix cancer may be initially misdiagnosed.
Male appendix cancer patients may be initially misdiagnosed as having a hernia, while female patients may be misdiagnosed as having ovarian cancer.
PMP Pals puts the "CAN DO!" in Cancer!®
We CAN outlive our prognosis!
We CAN live well in spite of a challenging and rare diagnosis!
We CAN find a cure for our rare disease!
Appendix Cancer Newsletter
Appendix Cancer Treatment Specialists
Appendix Cancer Frequently Asked Questions
What is the treatment for Appendix Cancer?
How is Appendix Cancer carcinoid treated?
What are Appendiceal Cancer treatments?
How is Appendix Cancer carcinoid treated?
What are Appendiceal Cancer treatments?
Appendix Cancer Treatment
Appendix cancer requires a specific treatment plan, provided by surgical oncologists who specialize in managing appendiceal cancer cases. Although we share the same basic "diagnosis" each case is different from others and each patient is truly unique.
Your surgical oncologist will explain and review all treatment options for your specific case.
Your treatment plan will depend on your overall health, the type of tumor (pathology), the quantity (mass) size and location of the tumor, and whether the cancer has metastasized.
Generally, treatment includes specialized surgery accompanied by HIPEC.
Systemic chemotherapy may be included in the treatment plan.
Appendix Cancer Surgery
Treatment for appendix cancer generally includes CRS or cytoreductive surgery with or without systemic chemotherapy and HIPEC.
The purpose of debulking surgery is to remove as much tumor as possible. Debulking surgery often includes the removal of the omentum and the right colon. Additionally, for women, debulking will likely include a hysterectomy, if this was not perfomed previously. Adhesions may become more troublesome with any additional debulking surgeries.
Cytoreductive surgery is a detailed, lengthy procedure often requiring ten or more hours.
Tumors are removed and destroyed using a variety of surgical techniques including argon beam coagulator, electro-evaporation, laser, and ultrasonic dissection.
CRS (cytoreductive surgery) consists of the removal of as much mucin and visible tumor as possible, from the abdominal cavity. CRS surgery, refers to the removal of all visible tumors present throughout the peritoneal cavity.
Cytoreductive Surgery includes thorough removal or destruction of all visible tumors throughout the surfaces of the peritoneum. Surgery may include the removal or resection of segments of small and large bowel, gall bladder, liver, omentum, ovaries, pancreas, spleen, stomach and uterus, and may require removing the lining of the peritoneum. Improved results are acheived when the surgeon is able to remove all visible tumor with minimal, or no deposits of residual disease (cancer.) The less residual disease, the better the opportunity for HIPEC to be effective.
CRS surgery for Appendix Cancer and Pseudomyxoma Peritonei may include the following:
Removal of the omentum, spleen and gall bladder,
Right hemicolectomy, colectomy, removal of the rectum and sigmoid,
Stripping tumor from the surface of the liver,
Resection of the pancreas,
Gastrectomy (partial or total removal of the stomach)
Stripping the peritoneum from left and right hemidiaphragm;
Pelvic peritonectomy,
Ileostomy, colostomy or urostomy
Although this procedure may initially sound challenging to the newly diagnosed patient, rarely is resection and/or removal of all of these organs is required.
Hemicolectomy is a surgical procedure involving the removal of a portion of the colon next to the appendix. This procedure may also include the removal of nearby blood vessels and lymph nodes at the same time.
HIPEC may be included at the conclusion of the cytoreductive surgery for the treatment of pseudomyxoma peritonei and appendix cancer if substantial tumor debulking is accomplished through CRS.
HIPEC may be administered when complete removal of visible tumor (or debulking) is achieved through cytoreductive surgery; it involves perfusion of the peritoneal cavity with chemotherapy heated to approximately 40 degrees Celsius.
HIPEC is administered with the infusion of heated chemotherapy during the last 90 minutes of the CRS procedure. Through HIPEC the surgeon(s) intend to destroy any residual tumor cells that may not have been surgically removed during the actual CRS surgery process.
Peritonectomy refers to stripping the parietal peritoneum and resecting structures at the sites that contain adenomucinosis. A combination of surgical techniques are utilized including organ resection, when necessary and tumor destruction via electro-evaporation and argon beam coagulation.
The peritoneum is the transparent serous membrane lining the cavity of the abdomen.
Steps to Prepare for Surgery
Source: Mercy Medical Center
Cytoreductive Surgery (includes graphic illustrations)
Source: Dr Paul Sugarbaker
FAQs about HIPEC
HIPEC
International directory of HIPEC treatment specialists including informational videos
HIPEC Chemo Perfusion
Source: UPMC Koch Cancer Center
Prepare for Surgery!
Pal Mentors assist you in preparing for surgery!
How are patients selected for appendix cancer surgery?
This question is frequently asked by newly diagnosed patients and “veteran” patients experiencing a “recurrence of disease.”
Why are some patients accepted for CRS or CRS/HIPC while others are not?
Is there any truth to the rumors that surgeons “cherry pick” their patients?
Why isn’t every patient a candidate for surgery?
Surgeons refer to the process of evaluating a surgical candidate as “patient selection.”
Many factors are taken into consideration for patient selection.
The success of CRS and HIPEC may be dependent on the:
patient’s overall general health,
complete removal of all tumor tissue,
location of tumor site(s) and
type of tumor (histology and differentiation.)
The following is a very general explanation of how patients are selected as surgical candidates:
1. Preliminary disease criteria
Patients with metastasis to the peritoneum, aka Peritoneal Carcinomatosis.
Patients with disease contained within the abdomen (without metastasis outside the abdomen)
2. Preliminary general health criteria for patient selection
Good overall heath lacking any major co-morbid conditions*.
Age (some surgeons limit the ages of patients they will accept into surgery)
Mental health (coherence, ability to understand instructions, evidence of chemical dependencies, etc.)
Ability to pay for surgery (adequate health insurance coverage or ability to pay out-of-pocket for medical care)
3. Preliminary review of patient medical history
Medical history including surgical history, if applicable, co-morbid conditions* (ie diabetes, lung or heart disease) current medications (prescribed and OTC) allergies and family history
History of present illness including summary of symptoms
Operative reports of previous surgeries
Pathology reports
Record of previous chemotherapy and radiotherapy treatments, if applicable, including dates and protocols
4. Extent of disease
Evaluation of CT scans to determine PCI (Peritoneal Cancer Index.)
The PCI helps the surgeon to determine the extent, volume and locations of the disease.
Evaluation of tumor block samples from original surgery(ies) if applicable.
Laparoscopy optional
Biopsy optional
Evaluation of tumor markers and associated lab tests
Physical examination of the patient
Surgery and Recuperation
Photo courtesy of Dr Jesus Esquivel
Dr Jesus Esquivel greets his 61 year old patient following appendix cancer CRS and HIPEC!
Ostomies
Systemic Chemotherapy for Appendix Cancer Treatment
Systemic chemotherapy may be included in your treatment plan.
Adjuvant Chemotherapy
Source: World Journal of Surgical Oncology, China 2008
ASCO reviews NEW chemotherapy trials for GI and Colon cancers
Source: ASCO 2009
Appendix Cancer Treatment with Avastin and Xeloda
Source: Cancer Bio Ther (Austria and China) Aug 2009
Appendix Cancer Pathology
Obtain a copy of, and review your pathology report.
A "final diagnosis" paragraph will clearly define your specific diagnosis, which may possibly include:
See descriptions of each of these diagnoses in paragraphs below...
Pseudomyxoma Peritonei,
Mucinous Adenocarcinoma,
Mucinous Cystadenoma,
Disseminated Peritoneal Adenomucinosis or DPAM,
Goblet Cell Carcinoid
Signet Ring Cell Carcinoma of the Appendix,
Peritoneal Carcinomatosis,
Peritoneal Surface Malignancy or other diagnoses
Pathology articles for your reference:
Pathophysiology of Appendix Cancer and related conditions
Source: Dr H Muller, Germany
Morphology (includes graphic color illustrations)
Source: Dr Paul Sugarbaker
Pathology
Clinicopathological Analysis of 22 Cases
Source: Dept of Pathology, China, 2009
Clinicopathologic Features of Mucinous Adenocarcinoma
Analysis of 46 patients following "second look" surgery
What's the difference between Adenomucinosis and Adenocarcinoma?
A: Dr. Brigitte Ronnett: "Adenomucinosis is pathologically and prognostic ally very different from adenocarcinoma. Adenomucinosis has very low-grade pathologic features and a better prognosis, although some patients can have more trouble with it than others.
Many patients get diagnosed with "adenocarcinoma" but we would classify these cases as adenomucinosis because they have a much better prognosis (and different pathology) than what we call adenocarcinoma. I hope more pathologists will adopt this classification system so that we can remove some of the mystery surrounding the behavior of PMP."
Q: GG states: "As you know, I write the PMP Pals newsletter from the perspective of patients. For the majority of us, our understanding of this topic (appendiceal cancer and/or Pseudomyxoma Peritonei) is rather limited. However, a clear understanding appears to be limited among local physicians as well.
Some patients become fearful to pursue treatment when they are given a dim prognosis from their local physicians. My goal is to encourage patients to educate themselves about their treatment options, with experienced specialists.
To my understanding, the first step in battling this disease is to confirm the diagnosis, then proceed in locating a qualified and experienced physician for specific treatment."
A: Dr. Brigitte Ronnett responds:
“These are the definitions pertaining to appendiceal cancer and Pseudomyxoma Peritonei:
Adenocarcinoma - malignant tumor that forms glands; this is what we refer to as the aggressive appendiceal tumors in the category PMCA in our papers.
Mucinous adenocarcinoma - a subtype of adenocarcinoma in which the glands have mucinous cytoplasm, sometimes producing abundant extracellular mucin (causing confusion with PMP/DPAM)
Adenocarcinoid - relatively unusual tumor, typically arising in the appendix, named for its histologic similarity to carcinoid tumor of the appendix (and other organs); combines features of carcinoid (usually goblet cell carcinoid) and adenocarcinoma; thought to possibly have behavior between benign and adenocarcinoma, but in our study we found that appendiceal adenocarcinomas with adenocarcinoid appearance usually are infiltrative and aggressive, so we consider them a variant of adenocarcinoma (they have areas that resemble goblet cell carcinoid of the appendix but also can have signet ring cells and others patterns of adenocarcinoma that are aggressive types of mucinous adenocarcinoma)
Disseminated peritoneal adenomucinosis (DPAM) - term created to describe the relatively bland peritoneal mucinous tumor associated with ruptured appendiceal adenomas and PMP; we use this term to distinguish these cases from the more aggressive cases of mucinous adenocarcinoma (PMCA.)
Some pathologists believe what we call DPAM should be called well differentiated mucinous carcinoma in the appendix and peritoneum in PMP cases but this makes the process sound like the other categories of mucinous carcinoma (PMCA and PMCA with intermediate features) and causes confusion; what we call well differentiated mucinous carcinoma (PMCA with intermediate features) is different from DPAM, although these two types can be more difficult to distinguish, and we have shown that DPAM has a better prognosis than the intermediate form of PMCA, warranting separated designation.
I think DPAM is the "true" PMP.”
Call us with your questions about Appendix Cancer!
Appediceal Adenocarcinoid
Appendiceal adenocarcinoid tumors and goblet cell carcinomas are similar to both carcinoid and adenocarcinoma tumors of the appendix.
DPAM
Disseminated peritoneal adenomucinosis (DPAM) describes a relatively bland peritoneal mucinous tumor associated with ruptured appendiceal adenomas and Pseudomyxoma Peritonei. This term is used to distinguish these cases from the more aggressive cases of mucinous adenocarcinoma (PMCA.)
Gastrointestinal Carcinoid
A Gastrointestinal carcinoid tumor is a cancer that develops in cells that make hormones in the lining of the the stomach and intestine, occuring in the appendix, rectum or small intestine.
Gastrointestinal carcinoid tumors form in cells that produce hormones along the lining of the gastrointestinal tract.
Gastrointestinal carcinoid tumors generally are considered to grow slowly, especially as when compared to other cancer tumors.
Patients with gastrointestinal carcinoid tumors may have an increased risk of developing cancers in the digestive system.
See Gastrointestinal Carcinoid Tumors for additional information (Source: NCI)
Goblet Cell Carcinoid
Mucinous Cystadenocarcinoma
Approximately 20% of appendix cancer cases are categorized as Mucinous Cystadenocarcinoma.
This type of tumor produces mucin that eventually fills the abdominal cavity causing distension, bloating, pain, shortness of breath and interference with digestive and bowel function.
Peritoneal Carcinomatosis
Peritoneal Carcinomatosis includes a variety of tumors that present with extensive metastasis throughout the peritoneal cavity. This description is used in conjunction with cancers and conditions of appendix, colon, gall bladder, ovaries, mesothelioma, pancreas, Pseudomyxoma Peritonei, rectal, sarcomas, small bowel, and stomach. When tumor develops from the peritoneum, it is referred to as Primary Peritoneal Surface Malignancy.
Symptoms of Peritoneal Carcinomatosis may initially be detected by appearing on as a diffused thickening of the peritoneum on a CT scan. The appearance of ascites refers to the accumulation of fluid within the peritoneal cavity and may occur for a variety of conditions including post operative inflammation or to cancer.
For Appendix Cancer and Psuedomyxoma Peritonei patients, ascites may appear as a rapid increase in fluid within in abdomen. This condition requires immediate medical attention.
See Peritoneal Carcinomatosis for additional information.
Peritoneal Surface Malignancy
Pseudomyxoma Peritonei
Appendix cancer may be characterized by the accumulation of mucoid material in the appendiceal lumen. Acellular mucin within the abdominal cavity is described as Pseudomyxoma Peritonei.
Pseudomyxoma Peritonei is a mucin-producing tumor usually originating from the appendix or ovaries. This is a rare condition in which cells have spread from the appendix or ovaries into the abdominal or peritoneal cavity resulting in mucinous tumor implants.
The Pseudomyxoma Peritonei mucin is very thick and viscous, often producing large tumors or clusters of tumors. These mucinous tumors enlarge causing bloating and abdominal distension. If left unchecked, mucinous tumors will eventually cause obstruction.
The mucin must be surgically removed. If left untreated, tumor cells and mucin can increase with time, eventually resulting in bowel obstruction, when the areas of the abdominal cavity and pelvis normally utilized for nutritional function and elimination, eventually become replaced by mucinous tumors.
Pseudomyxoma Peritonei generally develops as a small polyp-like growth, or adenoma, originating with the appendix. Eventually the adenoma breaks or tears through the appendix, spreading mucin or gelatinous ascites, throughout the peritoneum.
The mucin is thick and viscous, often producing large tumors or clusters of tumors. These mucinous tumors of gelatinous ascites, enlarge causing bloating and abdominal distension. If left unchecked, mucinous tumors will eventually cause bowel obstruction.
Due to the viscosity (density and gelatinous nature) of the mucinous tumors, they cannot be removed via paracentesis or liposuction.The mucin must be surgically removed.
Pseudomyxoma Peritonei is also described as an accumulation of mucus within the peritoneal cavity. Mucus secreting cells attach to the peritoneal lining and to organs within the peritoneal cavity and continue to secrete mucus.The mucus may originate the appendix, ruptured ovarian cysts, the appendix, or from other abdominal tissue.
Pseudomyxoma Peritonei generally remains within the peritoneum or abdominal cavity and rarely spreads via the blood or lymphatic systems.
Appendiceal carcinoid tumors represent approximately fifty per cent of all appendix tumor cases. Carcinoid tumors are usually less than two centimeters in size and rarely spread to lymph nodes.
Appendiceal non-carcinoid tumors originate from the epithelial cells lining the inside of the appendix. These cells create tumors producing mucin (a gelatinous material defined as Pseudomyxoma Peritonei.) These tumor cells and mucin can accumulate and increase gradually taking more space within the abdominal or peritoneal cavity.
If these mucin producing cells spread outside the appendix and into the peritoneal or abdominal cavity, they can lead to fatal bowel obstruction, if left untreated.
See Pseudomyxoma Peritonei for additional information.
Signet Ring Cell Adenocarcinoma of the Appendix
The diagnosis of Signet Ring Cell Adenocarcinoma of the Appendixmay be the most challenging listed under the broad description of Appendiceal Adenocarcinoma and/or Pseudomyxoma Peritonei.
Signet ring cell adenocarcinoma is a rare diagnosis and may be considered to be more aggressive and therefore more challenging to treat. Signet ring cell adenocarcinoma can develop in the appendix, colon or stomach.
Signet ring cell adenocarcinoma is considered to be the rarest and most aggressive of the appendiceal cancers and progresses more rapidly compared to other appendiceal cancers.
Signet ring cell adenocarcinoma commonly presents with the same symptoms as all other appendiceal cancers.
Diagnosis may be suspected based on physical symptoms, CT scans, and tumor marker tests.However, the actual diagnosis is confirmed by pathologists after examination of actual tissue and/or mucin or fluid samples.
Treatment may include surgery, including HIPEC and/or systemic chemo.
If you have been diagnosed with Signet Ring Cell Carcinoma originating with Appendix Cancer, consult with your specialist regarding the most thorough treatment plan for your particular diagnosis.
See Signet Ring Cell for additional information
Signet ring cell adenocarcinoma is a rare diagnosis and may be considered to be more aggressive and therefore more challenging to treat. Signet ring cell adenocarcinoma can develop in the appendix, colon or stomach.
Signet ring cell adenocarcinoma is considered to be the rarest and most aggressive of the appendiceal cancers and progresses more rapidly compared to other appendiceal cancers.
Signet ring cell adenocarcinoma commonly presents with the same symptoms as all other appendiceal cancers.
Diagnosis may be suspected based on physical symptoms, CT scans, and tumor marker tests.However, the actual diagnosis is confirmed by pathologists after examination of actual tissue and/or mucin or fluid samples.
Treatment may include surgery, including HIPEC and/or systemic chemo.
If you have been diagnosed with Signet Ring Cell Carcinoma originating with Appendix Cancer, consult with your specialist regarding the most thorough treatment plan for your particular diagnosis.
See Signet Ring Cell for additional information
Connect with Appendix Cancer Survivors!
Appendix Cancer Clinical Trials and Research
Clinical Trials
PET Scans for Appendix Cancer
Use of FDG-PET imaging for patients with disseminated cancer of the appendix.
Rohani P, Scotti SD, Shen P, Stewart JH, Russell GB, Cromer M, Levine EA.Surgical Oncology Service, Department of General Surgery, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Abstract
The goal of this study is to evaluate the use of positron emission tomography (PET) in evaluation of patients with peritoneal dissemination of carcinoma of appendiceal origin (PDA).
Thirty-three patients with PDA, who had preoperative PET or PET/CT imaging, were analyzed. Using operative, pathology, and PET +/- CT data, presence or absence of disease in each abdominal quadrant was noted and the use of 18fluoro-deoxy-glucose (FDG) PET for each quadrant was evaluated. The mean age was 52, and there were 17 males; 58 per cent had low-grade lesions.
PET was positive in only 35 per cent of cases overall (30 and 41% sensitivity for low-grade and high-grade, respectively). PET without CT sensitivity for low-grade and high-grade lesions was 21 and 8 per cent, respectively.
PET imaging has limited use for patients with PDA. We do not recommend the use of FDG-PET for patients with PDA from cancer of the appendix.Source: Am Surg, Dec 2010
CT Scan Articles
Am I Having Too Many CT Scans?
Source: PMP Pals' Network
CT Imaging used to assess surgical treatment for Appendix Cancer
Source: Journal Chirurgie, France, June 2009
Diagnostic Imaging for the detection of Pseudomyxoma Peritonei orginating with Appendix Cancer diagnosis
Source: Royal College of Radiologists, 2003
Tumor Grade
What does "tumor grade" refer to?
“Tumor grade” describes how much the tumor appears like normal tissue when examined under a microscope. The tumor grade helps physicians predict how quickly the cancer may grow.
G1: well-differentiated tumor cells
G2: moderately differentiated tumor cells
G3: poorly differentiated tumor cells
G4: undifferentiated tumor cells
Appendix Cancer Staging
“What is appendix cancer staging?"
“How is appendix cancer staged?”
Appendix cancer staging describes:
Where the cancer is located, where it has metastasized and whether it affects other organs.
Staging is determined from a series of diagnostic tests.
Staging helps physicians determine the most appropriate course of treatment.
Staging may also be used to assess the patient’s prognosis.
“What does TNM mean?”
TNM is an abbreviation for:
Tumor
Node (lymph nodes)
Metastasis (where the cancer has spread)
Appendix Cancer Prognosis and Long Term Survival
What it the prognosis for Appendix Cancer patients?
What are the long term survival statistics for Appendix Cancer patients?
How long will I survive with the diagnosis of Appendix Cancer?
The prognosis for patients diagnosed with appendix carcinoid tumors is often good.
In general, prognosis and long term survival have improved during the past decade, with earlier detection,
enhanced education of healthcare providers, including radiologists and pathologists, followed by referrals to specialists and improved methods of treatment.
Many factors contribute the prognosis and long term survival of patients. These factors may include pathology, staging at the time of diagnosis, overall health of the patient at the time of the diagnosis, age at the time of diagnosis, access to specialized care, etc. Long term survival may increase with early and accurate diagnosis, overall health of the patient at the time of diagnosis, the actual pathology/diagnosis itself, and appropriate treatment provided by a specialist.
Appendix carcinoid tumors, located at the tip of the appendix, of less than two centimeters in size, generally have a low risk of spreading to the lymph nodes.
Patients are encouraged not to accept the original dismal prognosis that may initially be offered by a non specialist. Each case is unique and each patient is an individual. Published statistics do not reflect the unique case of a newly diagnosed patient, whose options for long term survival are continually improving through modern medical treatment.
What are the long term survival statistics for Appendix Cancer patients?
How long will I survive with the diagnosis of Appendix Cancer?
The prognosis for patients diagnosed with appendix carcinoid tumors is often good.
In general, prognosis and long term survival have improved during the past decade, with earlier detection,
enhanced education of healthcare providers, including radiologists and pathologists, followed by referrals to specialists and improved methods of treatment.
Many factors contribute the prognosis and long term survival of patients. These factors may include pathology, staging at the time of diagnosis, overall health of the patient at the time of the diagnosis, age at the time of diagnosis, access to specialized care, etc. Long term survival may increase with early and accurate diagnosis, overall health of the patient at the time of diagnosis, the actual pathology/diagnosis itself, and appropriate treatment provided by a specialist.
Appendix carcinoid tumors, located at the tip of the appendix, of less than two centimeters in size, generally have a low risk of spreading to the lymph nodes.
Patients are encouraged not to accept the original dismal prognosis that may initially be offered by a non specialist. Each case is unique and each patient is an individual. Published statistics do not reflect the unique case of a newly diagnosed patient, whose options for long term survival are continually improving through modern medical treatment.
Appendix Cancer Prognosis and Long Term Survival Articles
CRS and HIPEC offer longterm survival rates for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
Diverticulosis patients with Appendix Cancer prognosis
Source: Journal of Surgical Pathology, 2009
Pseudomyxoma Peritonei and Appendix Cancer Prognosis following serial debulking
Source: University Central Hospital Helsinki, Finland, June 2009
Prognosis following Chemo Hyperthermic Profusion
Source: Fukai School of Medicine, Japan, April 2009
Appendix Cancer Prognosis for VEGF expression patients with Mucinous Adenocarcinoma
Appendix Cancer Prognosis and Survival Rates
Source: Dr Paul Sugarbaker, Washington Hospital Center
Appendix Cancer Prognosis
Source: Dr Paul Sugarbaker, Washington Hospital Center
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul Sugarbaker, 2005
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul Sugarbaker, 2005
Appendix cancer prognosis and survival rates following surgery and IP
Source: Mayo Clinic
Appendix Cancer Survivors!
PMP Pals' Survey: What do PMP Pals have in common?
When patients are diagnosed with appendiceal cancer and Pseudomyxoma Peritonei, one of the first questions they ask is "what do I have in common with other patients?"
Patients, and their families, are naturally curious about suspected common factors, therefore, in response to these, and other common questions, the PMP Pals' Network focused this year's annual survey on three topics of consideration:
Behavioral factors (use of tobacco, alcohol, diet, etc)
Environmental factors (exposure to chemicals, radiation, H Pylori, etc.)
Familial factors (family histories of bowel/colon diseases, UC, IBS, etc)
Three hundred patients responded to this survey as of July 28, 2011. Patients had the option of answering as many questions as they wanted to. Our software prevented patients from answering the survey more than one time.
This survey was conducted by and for the interest of the members of the PMP Pals' Network and is not intended to substitute for a scientific study. Patients (or their spouse caregivers on their behalf) responded to survey questions anonymously.
Dr Paul H Sugarbaker Reports on the Effects of Doxorubicin
Dr Paul H Sugarbaker Reports on the Effects of Doxorubicin for Appendix Cancer Treatment
Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis from colorectal and appendix cancer.
Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D.
Source: Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a combined treatment modalityperitoneal carcinomatosis from colorectal and appendiceal cancer. Doxorubicin is a drug consistently used by our group in this clinical setting. The surgical and clinical factors that modify the pharmacokinetics of HIPEC may be important for the design of future perioperative chemotherapy regimens.
MATERIALS AND METHODS: The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using CRS prior to treatment with HIPEC with doxorubicin as part of a multidrug regimen. The effect of clinical and surgical factors on drug distribution after a single intraperitoneal bolus administration with doxorubicin was determined.
RESULTS: The pharmacokinetics of 145 patients treated with intraperitoneal doxorubicin showed a 78 times greater exposure to peritoneal surfaces as compared to plasma. At 90 min 12% of the drug remained in the chemotherapy solution and 88% was retained in the body. The extent of visceral resection and peritonectomy increased the clearance of doxorubicin from the peritoneal space. A major resection of visceral peritoneal surface, a contracted peritoneal space, and an incomplete cytoreduction reduced drug clearance.
CONCLUSIONS: Surgical and clinical factors may require modifications of chemotherapy administration. A large visceral resection and a contracted peritoneal space caused a reduced doxorubicin clearance. Total diffusion surface is an important determinant of doxorubicin pharmacokinetics.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Appendix Cancer Research by Dr Paul H Sugarbaker
1. Sugarbaker PH. Twenty-three years of progress in the management of a rare disease. Dis Colon Rectum. 2011 Mar;54(3):265-6. PubMed PMID: 21304294.
2. Ortega-Deballon P, Glehen O, Levine E, Piso P, Sugarbaker PH, Hayes-Jordan A, Facy A, Bakrin N, Rat P. Childbearing After Hyperthermic Intraperitoneal Chemotherapy: Results From an International Survey. Ann Surg Oncol. 2011 Feb 11. [Epub ahead of print] PubMed PMID: 21311981.
3. Sugarbaker PH. Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? Am J Surg. 2011 Feb;201(2):157-9. Epub 2010 Sep 26. PubMed PMID: 20870209.
4. Catena F, Di Saverio S, Kelly MD, Biffl WL, Ansaloni L, Mandalà V, Velmahos GC, Sartelli M, Tugnoli G, Lupo M, Mandalà S, Pinna AD, Sugarbaker PH, Van Goor H, Moore EE, Jeekel J. Bologna Guidelines for Diagnosis and Management of Adhesive Small Bowel Obstruction (ASBO): 2010 Evidence-Based Guidelines of the World Society of Emergency Surgery. World J Emerg Surg. 2011 Jan 21;6:5. PubMed PMID: 21255429; PubMed Central PMCID: PMC3037327.
5. Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH; Peritoneal Surface Oncology Group. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011 Jan;98(1):60-4. doi: 10.1002/bjs.7263. Epub 2010 Sep 24. PubMed PMID: 20872843.
6. Ansaloni L, Andersson RE, Bazzoli F, Catena F, Cennamo V, Di Saverio S, Fuccio L, Jeekel H, Leppäniemi A, Moore E, Pinna AD, Pisano M, Repici A, Sugarbaker PH, Tuech JJ. Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. World J Emerg Surg. 2010 Dec 28;5:29. PubMed PMID: 21189148; PubMed Central PMCID: PMC3022691.
7. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacology of perioperative 5-fluorouracil. J Surg Oncol. 2010 Dec 1;102(7):730-5. doi: 10.1002/jso.21702. PubMed PMID: 21104923.
8. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2010 Nov 18. [Epub ahead of print] PubMed PMID: 21089100.
9. Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010 Nov 1;102(6):565-70. PubMed PMID: 20976729.
10. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010 Nov 1;102(6):576-81. PubMed PMID: 20737420.
11. Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2010 Sep 21. [Epub ahead of print] PubMed PMID: 20857115.
12. Sugarbaker PH. Revised guidelines for second-look surgery in patients with colon and rectal cancer. Clin Transl Oncol. 2010 Sep;12(9):621-8. PubMed PMID: 20851803.
13. Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol. 2010 Jun 15;101(8):713-24. Review. PubMed PMID: 20512948.
14. Sugarbaker PH. Five Reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal. Ann Surg Oncol. 2010 Jun;17(6):1710-2; author reply 1713-4. PubMed PMID: 20354799.
15. Zappa L, Savady R, Sugarbaker PH. Gastric perforation following cytoreductive surgery with perioperative intraperitoneal chemotherapy. J Surg Oncol. 2010 Jun 1;101(7):634-6. PubMed PMID: 20461773.
16. Sugarbaker PH. Pont hepatique (hepatic bridge), an important anatomic structure in cytoreductive surgery. J Surg Oncol. 2010 Mar 1;101(3):251-2. PubMed PMID: 20082353.
17. Zappa L, Sugarbaker PH. Mesenteric cyst: report of a case-resulting in pseudomyxoma peritonei. Tumori. 2010 Mar-Apr;96(2):332-5. PubMed PMID: 20572595.
Appendix Cancer Survivors!
Q&A: "Is Appendix Cancer Hereditary?"
Case of Siblings with Appendix Cancer
Appendiceal Mucinous Adenocarcinoma:
Primary appendiceal mucinous adenocarcinoma in two first-degree relatives: case report and review.
Source: Racek AR, Rabe KG, Wick MJ, Psychogios A, Lindor NM.Department of Medical Genetics, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, USA. nlindor@mayo.edu.
ABSTRACT: Carcinomas of the appendix are exceedingly rare tumors and have an annual age-adjusted incidence of around 0.4 cases per 100,000. Appendiceal adenocarcinoma accounts for < 0.5% of all gastrointestinal neoplasms and, of these, mucinous adenocarcinomas account for the majority.
Published accounts of familial instances of primary appendiceal tumors are strikingly rare. We report two siblings who both developed primary mucinous adenocarcinomas. A genetics evaluation was conducted to determine if there was a recognizable underlying single gene disorder; no DNA mismatch repair defect was evident, and no other diagnosis was apparent.
A review of appendiceal cancers seen at Mayo Clinic from l997 to the present was conducted to search for additional familial cases. Among 316 cases of primary appendiceal cancer of any histologic type, this sib pair was the only family reporting a second affected family member. The occurrence of appendiceal cancer in siblings may represent a random occurrence.
An exceedingly rare predisposition syndrome cannot be ruled out.
Source: PMID: 21542938 [PubMed - in process] PMCID: PMC3098790
Hereditary or Familial Cancers
Hereditary Cancers including gastric and colon cancers
Source: Creighton University
Hereditary Cancer Genes
Source: Creighton University
Hereditary Cancers including colorectal cancers
Source: MD Anderson
Hereditary Cancers including colorectal cancers: testing, genetics and more
Source: Memorial Sloan Ketting
Genetic Screening Program
Source: Wake Forest University
Here's what families say about the PMP Pals' Network...
“PMP Pals provided invaluable suggestions and information on treatment options for my husband's rare cancer diagnosis. The information provided is extensive and research based. The director of PMP Pals is knowledgeable and compassionate. Without the services of PMP Pals, my husband would not have survived his initial diagnosis and treatment, primarily because the local physicians did not know how to treat the disease."
SR, USA, wife of a patient of Dr David L Bartlett
Dr Paul Sugarbaker Provides List of Abbreviations Describing Surgery and HIPEC
Dr Paul Sugarbaker
Thank you to Dr Paul Sugarbaker for providing the PMP Pals' Network with this listing of abbreviations commonly used for the treatment of Appendiceal Cancer.
For additional information see our Appendix Cancer Glossary.
1. CS – Chemosurgery (most general abbreviation includes CRS, HIPEC, EPIC and ABC)
2. HIPEC – Hyperthermic intraperitoneal chemotherapy
3. HIPEC + 5FU – Hyperthermic intraperitoneal chemotherapy plus intravenous 5-fluorouracil
4. HIPEC + IFO – Hyperthermic intraperitoneal chemotherapy plus intravenous ifosfamide
5. EPIC – Early postoperative intraperitoneal chemotherapy usually 5-FU or paclitaxel
6. ABC – Adjuvant bidirectional chemotherapy
7. CRS – Cytoreductive surgery
8. CCRS – Complete cytoreductive surgery
9. PM – Peritoneal metastases (should replace PC)
10. PC – Peritoneal carcinomatosis
11. POC – Perioperative chemotherapy
12. LM – Liver metastases
13. LNM – Lymph node metastases
14. LR – Local-regional
15. IP port – Intraperitoneal port used for ABC
16. Tenckhoff catheter – Temporary catheter used to deliver EPIC
Appendiceal Cancer Terminology
Appendix Cancer Definitions
Appendix Cancer Neoplasms
Primary Neoplasms of the Appendix: Radiologic Spectrum of Disease with Pathologic Correlation
Perry J. Pickhardt, LCDR, MC, USNR, Angela D. Levy, LTC, MC, USA, Charles A. Rohrmann Jr, MD and Amir I. Kende, Maj, MC, USAF
Appendix Cancer Definitions and Treatments
Source: National Cancer Institute, USA
Appendix Cancer Definitions and Analysis
What is the Appendix? Definition
Source: MedicineNet.com
What is an Adenocarcinoma as Appendix Cancer?
Source: Bioline
Atlas of Appendix Cancer(includes graphic illustrations)
Source: Dr Paul Sugarbaker
Characterizations of Appendix Cancer; Adenocarcinoid
Source: The Doctors' Doctor
Appendix Cancer, Carcinoid
Source: Mayo Clinic
Appendix Cancer Carcinoma
Source: Viszeralmedizin, 2003
Appendix Cancer Defined
Source: MD Anderson
Appendix Cancer Articles
Articles by Dr David L Bartlett
Dr David L Bartlett, Dr James Pingpank, Dr Steven Ahrendt
Source: Koch Cancer Treatment Center, UPMC
Articles by Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Dr Jesus Esquivel:St Agnes Hospital
Source: St Agnes Hospital
Articles by Dr Martin Goodman
Dr Martin Goodman at Tufts University provides HIPEC
Source: Tufts University, Boston
Dr Andrew Lowy
Dr Andrew Lowy: Moores Cancer Center
Source: UCSD
Articles by Dr Armando Sardi
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Steps to Prepare for Surgery
Source: Mercy Medical Center
Articles by Dr Perry Shen
Dr Perry Shen at WFTU provides HIPEC
Source: Wake Forest University
Articles by Dr Paul Sugarbaker
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
Cytoreductive Surgery (includes graphic illustrations) Source: Dr Paul Sugarbaker
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Abstract: Epithelial neoplasms of the appendix.
Submitted byTang LH.
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. tangl@mskcc.org
CONTEXT: The appendix gives rise to an array of epithelial neoplasms showing glandular or neuroendocrine differentiation, and some tumors with elements of both cell types. Although some appendiceal neoplasms resemble their counterparts in the small and large intestines (conventional adenocarcinoma and carcinoid tumor), the appendix also gives rise to relatively unique entities including mucinous neoplasms and goblet cell carcinoid tumors, which present a challenge in pathologic classification and clinical management.
OBJECTIVE: To review clinical and diagnostic issues for 3 pathologic types of epithelial neoplasms of the appendix: (1) adenocarcinoma, with specific focus on mucinous neoplasm; (2) goblet cell carcinoid tumor and associated adenocarcinoma; and (3) typical carcinoid tumor.
DATA SOURCES: Case-derived material and literature review.CONCLUSIONS: The most important issue in pathologic assessment of epithelial tumors of the appendix is to understand the clinical implications inherent in the diagnosis.
Appendix Cancer Treatment with Chemo Hyperthermic Peritoneal Perfusion (CHPP)
Source: Pub Med 2009
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Study of Appendix Cancer Treatments
Source: ESJO, 2004
Universite de Montreal for CRS and HIPEC
Source: Universite de Montreal, Canada, 2009
Peritonectomy, Surgery
Source: Dr H Muller
Phase I Trial
Source: ClinicalTrials.gov, 2009
International Consensus of PSMG for CRS and HIPEC
Source: Springerlink, Oct 2006
Appendix Cancer Nutrition
Nutrition for Appendix Cancer Patients
Patients may experience specific nutritional needs following surgery.
For specific information regarding your personal nutritional needs, consult with a registered dietician/nutritionist and provide him/her with a copy of your operative report.
Dr Paul Sugarbaker tells us: "Digestion actually begins with the chewing motion!"
As we chew, foods are broken into smaller particles so they can be processed in the stomach and intestinal track. The purpose of digestion is to extract vital nutrients that our bodies need to maintain health and to recover from illness and surgery.
Vital nutrients include calories, protein, carbohydrates, fats, vitamins and minerals, in addition to water. Nutrients are primarily absorbed through the small intestine into the blood stream where they are carried throughout the body and put to work keeping out organs functioning properly. On average, we consume about 2 liters of food and liquid daily. Nutrients our bodies don't need are excreted through the urinary track and large intestine.
Digestive Distress Following Appendix Cancer Surgery
Digestive Distress (Gas) Following Appendix Cancer Surgery
Gastrointestinal cancer patients, and the public in general, are often caught in the dilemma between eating a healthy diet and suffering from the pain, bloating, flatulence (gas) and associated distress that accompanies many common foods.
These problems may be exacerbated for Appendix cancer patients, especially following surgery and/or chemotherapy treatments.
In today's article we provide general information regarding common complaints among our fellow gastrointestinal cancer patients. Consult with your health care provider regarding your specific personal needs.
It is a normal condition to have air travel through the digestive system. The average adult produces up to two quarts of air (gas) daily. Gas may be produced by the foods you eat or when air is swallowed when you eat, drink or chew gum. Some medications, including antihistamines, and calcium channel blockers may contribute to gas production.
Gas Producing Foods
Confused about gas producing foods? The following foods may be some of the “culprits” that you may have overlooked!
Bagels, Beans, Bleu Cheese, Bread, (Carbohydrates) Broccoli, Brussell Sprouts, Buttermilk, Cabbage, Carbonated beverages, Cauliflower, Corn Flakes, Crackers, Fried and Fatty foods, Fructose (natural sugar) Peanuts, Peas, Potatoes, Ranch dressing, Sorbitol (artificial sweetener)
High fiber foods
Intestinal cancer patients may experience difficulties in digesting a high fiber diet
and should consult with their physician before adding or deleting foods from their meal plans.
Common high fiber foods include:
Apples, Artichokes, Asparagus, Beans, Bran, Brussell sprouts, Cabbage, Carrots, Celery, Peas, Pineapple, and whole grains
Gluten Sensitivity
Patients affected by Celiac Disease may be unable to consume whole grains. For more information about gluten sensitivity, see the Celiac Disease Nutrition page on www.pmppals.org
Laxatives
Laxatives should only be used after consulting with a physician. Bulk forming laxatives are taken with water, absorb water in the intestine and make the stool softer.
These laxatives may interfere with the absorption of some medications:
Citrucel,Metamucil,Konsyl,Serutan
Stimulant laxatives cause intestinal rhythmic muscle contractions:
Correctol,Ducolax,Feen a Mint,Purge,Senokot
Stool softeners add moisture to the stool and may be prescribed following surgery:
Colace,Dialose,Mineral Oil
Saline laxatives draw water into the colon for easier stool passage:
Citrage of Magnesia,Haley’s M O,Milk of Magnesia
Diarrhea
Diarrhea may occur following gastrointestinal surgery and may accompany chemotherapy.
Foods and beverages that may aggravate diarrhea:
Coffee, High fiber foods, Milk, Milk based foods (ice cream, yogurt) Raw vegetables, Strong tea
Foods that may ease diarrhea:
Applesauce, Bananas,Rice, Toasted bread
Medication to combat diarrhea (consult with your physician):
Immodium, Lomotil, Sandostatin
For more information about Diet, Nutrition, Malabsorption and intestinal distress, visit the
NUTRITION link at www.pmppals.org
Copyright 2011 by Gabriella Graham/PMP Pals' Network/All rights reserved
Obstructions
Stomach Cancer
Gastric Cancer
Stomach cancer surviorship improves with chemotherapy
Source: JAMA, May 2010
Stomach Cancer increasing in young adult population
Source: NIH/MDAnderson/Google News, May 2010
What Causes Cancer?
Organic Foods May Reduce Cancer Risks
Source: President's Council and PRN, May 2010
Chemical Exposures and Cancer Risks
Source: President's Council per LA Times, May 2010
Cancer and Your Environment
Source: Dept of Health, Illinois
Risk Factors for Cancer
Source: Merck
Risk Factors for Colorectal Cancer
Source, ACS, Feb 2010
Source: President's Council and PRN, May 2010
Chemical Exposures and Cancer Risks
Source: President's Council per LA Times, May 2010
Cancer and Your Environment
Source: Dept of Health, Illinois
Risk Factors for Cancer
Source: Merck
Risk Factors for Colorectal Cancer
Source, ACS, Feb 2010
Appendix Cancer Support
Have you recently been diagnosed with Appendix Cancer?
Are you currently receiving treatment for Appendix Cancer?
Are you "veteran Pal" and now disease free from Appendix Cancer?
View photos and mini profiles of fellow Appendix Cancer Survivor Pals!
Here's what patients say about their Pal Mentors!
"Thank you to our Pals Mentors for sharing your collective wisdom with us; it's exactly what we needed! It has been so helpful to talk with someone who has been through surgery before. I think are really benefiting from being active members of the PMP Pals' Network!" AC, USA, family of a patient of Dr H Richard Alexander
The PMP Pals' Network updates our website 364 days per year with a wide variety of new information to keep you informed about maintaining optimal health! Whether you seek information about research studies, health insurance, personal mentoring, diet and exercise, new treatment options, and so much more, the PMP Pals' Network is your "go to" place for information!
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
This web page is sponsored in loving memory of Jon Bogdanoff by his family and friends.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright 2012 by PMP Pals' Network/Gabriella Graham/All rights reserved. Updated 01.28.12
